Literature DB >> 6131488

Benzodiazepine withdrawal effects.

J C Pecknold, D J McClure, D Fleuri, H Chang.   

Abstract

1. Twenty-nine patients with anxiety neurosis who had completed a one week placebo, three week active drug study on either halazepam or oxazepam were observed for eight weeks for withdrawal effects. Half of the patients received a placebo for the first two weeks of the withdrawal study and half had all medication abruptly stopped. 2. There was no significant difference in the pattern of withdrawal between halazepam, an intermediate range benzodiazepine, and oxazepam, a short acting benzodiazepine. 3. Withdrawal symptoms were apparent, maximally between week 1 and 2 together with possible rebound effects. 4. Patients who received placebo had significantly less severe withdrawal symptoms than those who had their medication abruptly discontinued.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6131488     DOI: 10.1016/s0278-5846(82)80142-5

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

1.  Treatment of triazolam dependence with a tapering withdrawal regimen.

Authors:  A N Singh; M Chemij; J Jewell
Journal:  CMAJ       Date:  1986-02-01       Impact factor: 8.262

Review 2.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

3.  Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects.

Authors:  R R Griffiths; D R McLeod; G E Bigelow; I A Liebson; J D Roache
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 4.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.